FWBI

First Wave BioPharma, Inc.

FWBI | $2.59 -8.8% -9.65% 83K

(0.0% 1d) (-38.7% 1m) (5.2% 1y) (0.0% 2d) (-2.1% 3d) (-13.1% 7d) (-24.56% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 5,245,265
https://www.azurrx.com
Sec Filling | Patents | 12 employees

(US) AzurRx BioPharma, Inc. is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI assets. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, FW-420, for grade 1 Immune Checkpoint Inhibitor Colitis and diarrhea in oncology patients and FW-1022, for COVID-19 gastrointestinal infections. The Company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California.

covid disease treatment phase 2 biopharma diarrhea fibrosis clinical trials test gastrointestinal trials trial pancreatic injection

add to watch list Paper trade email alert is off

Press-releases

First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase
Published: 2024-04-17 (Crawled : 11:00) - globenewswire.com
FWBI | $2.59 -8.8% -9.65% 83K

Manufacturing

| -8.68% | O: -5.79% H: 4.1% C: -1.02%
first ceo biopharma microcap

First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
FWBI | $2.59 -8.8% -9.65% 83K

Manufacturing

| -17.68% | O: 0.29% H: 2.6% C: -5.49%
first ceo conference biopharma leaders

First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
Published: 2024-03-18 (Crawled : 11:00) - globenewswire.com
FWBI | $2.59 -8.8% -9.65% 83K

Manufacturing

| -40.08% | O: 0.21% H: 4.21% C: 2.53%
first conference disease presentation biopharma research week

First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline
Published: 2024-03-14 (Crawled : 10:00) - globenewswire.com
FWBI | $2.59 -8.8% -9.65% 83K

Manufacturing

| -56.51% | O: -3.52% H: 0.16% C: -14.76%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -5.82% | O: 0.23% H: 0.0% C: 0.0%
first business pipeline biopharma

First Wave BioPharma to Participate In ‘Fireside Chat’ at the 36th Annual Roth Conference
Published: 2024-03-05 (Crawled : 12:00) - globenewswire.com
FWBI | $2.59 -8.8% -9.65% 83K

Manufacturing

| -59.6% | O: 0.14% H: 17.19% C: 10.94%
first conference biopharma

First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct Offering
Published: 2024-03-04 (Crawled : 13:00) - globenewswire.com
FWBI | $2.59 -8.8% -9.65% 83K

Manufacturing

| -69.26% | O: -13.96% H: 6.3% C: -11.57%
first million direct offering

First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024
Published: 2024-02-13 (Crawled : 12:00) - globenewswire.com
FWBI | $2.59 -8.8% -9.65% 83K

Manufacturing

| -48.27% | O: -0.18% H: 0.36% C: -8.94%
first ceo conference biopharma

First Wave BioPharma to Present at the DealFlow MicroCap Conference
Published: 2024-01-23 (Crawled : 12:00) - globenewswire.com
FWBI | $2.59 -8.8% -9.65% 83K

Manufacturing